Traders should monitor the timing of the 80th event in the REGAL trial, which will trigger unblinding and topline results — a potential value inflection point. The expanded SLS009 program and strong cash position reduce near-term dilution risk, but profitability remains distant.
Price Chart
Executive Summary
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash position bolstered by $42.6 million in warrant exercises in Q1 2026. The company highlighted clinical progress in its GPS and SLS009 programs for AML, including positive Phase 2 data for SLS009 and advancement toward the final analysis of the Phase 3 REGAL trial. No revenue was generated, as the company remains in late-stage development.
Key Financial Metrics
Key Facts
- Net loss narrowed to $26.9 million in 2025 from $30.9 million in 2024, with EPS improving from -$0.50 to -$0.25.
- Cash and cash equivalents totaled $71.8 million as of December 31, 2025, with an additional $42.6 million received in Q1 2026 from warrant exercises.
- Phase 3 REGAL trial for GPS in AML has recorded 72 of 80 required events; final analysis pending unblinding after 80th event.
- SLS009 showed a 46% overall response rate in r/r AML patients, with higher rates in high-risk molecular subtypes (ASXL1: 48%, TP53: 57%).
- First patient dosed in a new Phase 2 trial of SLS009 in newly diagnosed AML patients, expanding into earlier lines of therapy.
Financial Impact
Reduced R&D spend by $3.1 million YoY; cash runway extended significantly with $114.4M total cash post-Q1 2026 warrant exercises.
Risk Factors
- REGAL trial results are event-driven and unblinded data could be negative, leading to significant downside.
- No product revenue; company remains dependent on clinical success and future financing or partnerships.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259428 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | Press Release | $11.61 | awaiting T+60 | — | $11.44 (−1.46%) |
Jun 2, 2026 21w ago | 8-K | $8.33 $13.73 | ▲ +64.83% | ▲ +63.71% | $11.44 (+37.33%) |
May 12, 2026 23w ago | 8-K | $6.53 $12.01 | ▲ +83.92% | ▲ +79.48% | $11.44 (+75.19%) |
Apr 23, 2026 26w ago | DEFA14A | $4.46 $12.90 | ▲ +189.24% | ▲ +184.16% | $11.44 (+156.50%) |
Mar 19, 2026 31w ago | Press Release | $4.76 $7.83 | ▲ +64.50% | ▲ +50.08% | $11.44 (+140.34%) |
Mar 17, 2026 31w ago | Press Release | $4.95 $7.75 | ▲ +56.57% | ▲ +45.04% | $11.44 (+131.11%) |
Mar 12, 2026 32w ago | Press Release | $5.03 $8.23 | ▲ +63.62% | ▲ +52.92% | $11.44 (+127.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers